Aburaihan Pharmaceutical Company (DABUR) cash flow statement

Name: Aburaihan Pharmaceutical Company (DABUR) cash flow statement
Creator: فاندای
License: https://fundai.ir/en/regulations

Operating, investing and financing cash flows, and the closing balance

Latest periods

Latest 6-month periods, in million rials
Item	To 1405/06/31	To 1404/06/31	To 1403/06/31	To 1402/06/31	To 1401/06/31	To 1400/06/31
Cash generated from operations	1,930,457	3,918,012	2,013,096	773,386	1,614,150	-337,545
Net cash inflow (outflow) from operating activities	1,930,457	3,805,639	1,776,503	323,715	1,434,503	-356,855
Cash payments for purchase of property, plant and equipment	-2,039	-39,649	-38,182	-50,229	-52,496	-44,170
Cash receipts from interest on other investments	1,484	1,465	847	1,091	5,125	2,101
Net cash inflow (outflow) from investing activities	-555	-4,774	-20,256	-36,872	-36,987	-61,316
Net cash inflow (outflow) before financing activities	1,929,902	3,800,865	1,756,247	286,843	1,397,516	-418,171
Cash receipts from facilities	5,987,901	2,644,036	2,790,603	6,648,067	3,203,104	4,110,000
Cash payments for principal of loans	-5,914,331	-2,927,398	-3,388,423	-5,206,666	-3,307,767	-2,836,642
Cash payments for interest on loans	-456,099	-2,836,969	-920,583	-736,365	-534,304	-365,565
Cash payments for dividends	-1,142,960	-511,274	-382,249	-588,095	-353,124	-449,354
Net cash inflow (outflow) from financing activities	-1,525,489	-3,654,462	-1,900,652	124,440	-992,091	465,945
Net increase (decrease) in cash	404,413	146,403	-144,405	411,283	405,425	47,774
Cash balance at beginning of year	563,502	481,194	393,878	615,561	589,822	206,527
Effect of changes in exchange rates	241,801	23,325	2,433	383	332	557
Cash balance at end of year	1,209,716	650,922	251,906	1,027,227	995,579	254,858

79 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.